Nothing Special   »   [go: up one dir, main page]

ATE266022T1 - Imidazol derivate als raf kinase inhibitoren - Google Patents

Imidazol derivate als raf kinase inhibitoren

Info

Publication number
ATE266022T1
ATE266022T1 AT01907974T AT01907974T ATE266022T1 AT E266022 T1 ATE266022 T1 AT E266022T1 AT 01907974 T AT01907974 T AT 01907974T AT 01907974 T AT01907974 T AT 01907974T AT E266022 T1 ATE266022 T1 AT E266022T1
Authority
AT
Austria
Prior art keywords
sub
sup
alkyl
optionally substituted
hydrogen
Prior art date
Application number
AT01907974T
Other languages
English (en)
Inventor
Jon Graham Steadman
Andrew Kenneth Takle
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0005370A external-priority patent/GB0005370D0/en
Priority claimed from GB0005387A external-priority patent/GB0005387D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE266022T1 publication Critical patent/ATE266022T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01907974T 2000-03-06 2001-03-02 Imidazol derivate als raf kinase inhibitoren ATE266022T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0005370A GB0005370D0 (en) 2000-03-06 2000-03-06 Compounds
GB0005387A GB0005387D0 (en) 2000-03-06 2000-03-06 Compounds
PCT/GB2001/000908 WO2001066539A1 (en) 2000-03-06 2001-03-02 Imidazol derivatives as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE266022T1 true ATE266022T1 (de) 2004-05-15

Family

ID=26243806

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907974T ATE266022T1 (de) 2000-03-06 2001-03-02 Imidazol derivate als raf kinase inhibitoren

Country Status (8)

Country Link
US (2) US7235658B2 (de)
EP (1) EP1263753B1 (de)
JP (1) JP2003525936A (de)
AT (1) ATE266022T1 (de)
AU (1) AU2001235838A1 (de)
DE (1) DE60103136T2 (de)
ES (1) ES2218391T3 (de)
WO (1) WO2001066539A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518032A (en) * 1999-11-22 2004-02-27 Smithkline Beecham Plc Substituted imidazole derivatives
EP1263753B1 (de) * 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivate als raf kinase inhibitoren
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
EP1432699A1 (de) 2001-09-05 2004-06-30 Smithkline Beecham Plc Pyridylfurane und -pyrrole als raf-kinasehemmer
EP1432703A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
AU2003226211B2 (en) * 2002-03-29 2008-05-29 Novartis Vaccines And Diagnostics, Inc. Substituted benzazoles and use thereof as RAF kinase inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US7268139B2 (en) 2002-08-29 2007-09-11 Scios, Inc. Methods of promoting osteogenesis
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
CN1889951A (zh) 2003-10-16 2007-01-03 希龙公司 取代的苯并唑及其用作raf激酶抑制剂的应用
US20050282909A1 (en) * 2003-11-14 2005-12-22 Diks Sander H Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction
US7250434B2 (en) 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
EP1676574A3 (de) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
PE20070427A1 (es) 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
WO2008150015A1 (en) 2007-06-05 2008-12-11 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
CA2695004C (en) 2007-07-17 2016-01-19 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
EP2184285B1 (de) 2007-08-29 2015-11-04 Takeda Pharmaceutical Company Limited Heterocyclische verbindung und ihre verwendung
EP2399921B1 (de) 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Heterocyclische verbindung und deren verwendung
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
IL311471A (en) 2017-05-02 2024-05-01 Novartis Ag Combined treatment

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR75287B (de) * 1980-07-25 1984-07-13 Ciba Geigy Ag
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE69637948D1 (de) 1995-10-06 2009-07-23 Merck & Co Inc Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
WO1997047618A1 (en) * 1996-06-10 1997-12-18 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
DE1049664T1 (de) 1997-12-22 2001-05-03 Bayer Corp., Pittsburgh Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
NZ526958A (en) 1998-05-22 2004-12-24 Smithkline Beecham Corp Novel 2-alkyl substituted imidazole compounds
US6691178B1 (en) * 2000-02-22 2004-02-10 Stmicroelectronics, Inc. Fencepost descriptor caching mechanism and method therefor
EP1263753B1 (de) 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivate als raf kinase inhibitoren
GB0005357D0 (en) * 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
ES2242767T3 (es) * 2000-09-21 2005-11-16 Smithkline Beecham Plc Derivados de imidazol como inhibidores de quinasa raf.
US20040053943A1 (en) * 2000-11-20 2004-03-18 Adams Jerry L. Novel compounds
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121494D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
EP1432699A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Pyridylfurane und -pyrrole als raf-kinasehemmer
ATE403653T1 (de) * 2001-09-05 2008-08-15 Smithkline Beecham Plc Pyridin-substituierte furanderivate als raf- kinase inhibitoren
EP1432703A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121490D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds

Also Published As

Publication number Publication date
US7235658B2 (en) 2007-06-26
DE60103136D1 (de) 2004-06-09
EP1263753B1 (de) 2004-05-06
ES2218391T3 (es) 2004-11-16
WO2001066539A1 (en) 2001-09-13
DE60103136T2 (de) 2004-10-28
EP1263753A1 (de) 2002-12-11
US20060122207A1 (en) 2006-06-08
US20030153588A1 (en) 2003-08-14
AU2001235838A1 (en) 2001-09-17
JP2003525936A (ja) 2003-09-02

Similar Documents

Publication Publication Date Title
ATE266022T1 (de) Imidazol derivate als raf kinase inhibitoren
DE60103133D1 (de) Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren
TW200611907A (en) Fused heterocyclic compound
NO20062633L (no) Pyrazolderivater som proteinkinasemodulatorer
RU2007110629A (ru) Ингибиторы днк-пк
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
ATE556058T1 (de) 1-(2h)-isochinolonderivat
EP1259487B8 (de) 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren
EA201170196A1 (ru) Производные бензазепинов и их применение в качестве h3 гистаминовых антагонистов
CY1115171T1 (el) Ιατρικο φαρμακο
ATE164575T1 (de) Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer
ATE472535T1 (de) Pyrimidinmatrixmetalloproteinaseinhibitoren
HRP20040429B1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
DE60115465D1 (de) Immunoregulierende verbindungen, deren derivate und ihre verwendung
EA200701780A1 (ru) Противоопухолевое средство
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
ATE403653T1 (de) Pyridin-substituierte furanderivate als raf- kinase inhibitoren
ATE305930T1 (de) Substituierte benzopyran derivate gegen arrhythmie
DE602006010702D1 (de) Homomorpholinoxazolidinone als antibakterielle mittel
UA74341C2 (uk) Похідні борелідину, які інгібують ангіогенез
IS7911A (is) Ímídasólafleiður með sækni í alfa 2 viðtakavirkni
DK0504290T3 (da) Inhibitorer af dihydrofylatreduktase fra Pneumocystis carinii
MY144464A (en) Pyrazole derivatives as protien kinase modulators
MX2008002753A (es) Derivados de piridazinona utilizados para el tratamiento de dolor.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties